TrialAmerican journal of clinical dermatology2026

Safety and Tolerability of Ruxolitinib Cream in Adolescents with Mild-to-Moderate Atopic Dermatitis: Results From a 1-Year, Phase III, Open-Label Study.

Joel C Joyce et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.